LianBio announced that CAMZYOS has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy from the Singapore Health Sciences Authority. Marketing approval in Singapore was based on data from the Phase 3 EXPLORER-HCM trial. Results from the Phase 3 EXPLORER-HCM trial, which evaluated CAMZYOS in patients with symptomatic obstructive HCM versus placebo, met all primary and secondary endpoints with statistical significance. In EXPLORER-HCM, CAMZYOS demonstrated a clear treatment effect, with clinically meaningful improvements in exercise capacity and symptoms, and functional status, as well as clinically meaningful improvement in left ventricular outflow tract obstruction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LIAN:
- LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
- LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
- LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
- LianBio to Participate in Upcoming Investor Conferences
- LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update